Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on May 24, 2021. The registrant is a Delaware corporation headquartered in Alameda, California, and is classified as an emerging growth company. The report discloses a specific financial event occurring on the date of the report.
Key Financial Metrics
The filing details a specific borrowing event rather than comprehensive financial statements.
- New Debt Incurred: $1.0 million borrowed on May 24, 2021.
- Lender: Juvenescence Limited.
- Facility: Loan Facility Agreement dated August 13, 2019, as amended February 10, 2021.
- Repayment Date: February 14, 2022.
- Revenue, Profit, Cash Flow, and Margins: The filing text does not provide a clear value for these metrics.
- Total Outstanding Debt: The filing text does not provide a clear value for the total outstanding principal balance prior to this new draw.
Material Changes
The primary material change reported is the increase in direct financial obligations. AgeX utilized an additional $1.0 million of available credit under its existing loan facility. This action increases the company's immediate debt load and liquidity requirements, with the full principal balance due on the specified Repayment Date.
Outlook, Risks, and Contingencies
Management Commentary and Forward-Looking Statements: The filing includes standard disclaimers regarding forward-looking statements, noting that actual results may differ materially from anticipated results due to various risk factors.
Events of Default: The loan agreement contains extensive default provisions that could accelerate the repayment of the entire outstanding balance. Key triggers include:
- Failure to pay amounts due within 10 business days of the due date.
- Failure to perform obligations under the agreement within 10 business days of notice.
- Other indebtedness exceeding $100,000 becoming due early, or indebtedness exceeding $25,000 not being paid when due.
- General cessation of payments, insolvency, or liquidation.
- Material adverse changes in financial condition affecting the ability to perform obligations.
- Legal judgments or injunctions materially affecting business operations.
Investor Verification Checklist
- Verify the total outstanding principal balance under the Loan Agreement with Juvenescence Limited as of May 24, 2021.
- Confirm the company's current cash position and liquidity runway relative to the February 14, 2022, repayment date.
- Review recent periodic reports (10-K/10-Q) for updated "Risk Factors" regarding the company's financial condition and solvency.
- Check for any subsequent filings indicating a default event or amendment to the loan terms.